Thynk Capital possess a historical investment performance in the top 1% of venture capital. Focused on investments in early stage pharma and biotech companies focused on extending HealthSpan and major diseases of Aging including Alzheimer's, Dementia, Kidney Disease, Cancer, Cardiovascular, Diabetes, Frailty, and Rare Disease which affect over 25% of the population and growing at 10%/year.
Focus Areas
Investment Types
Notable Investments
